EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that there has been a slight increase in ...
Research firm Decision Resources predicts that the rheumatoid arthritis market will modestly grow to $15 billion in the next decade. RA patients already have access to more than enough drugs to find ...
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...
A few days ago, I published an AbbVie (ABBV) article titled "AbbVie: The Humira Situation Remains Scary". In that article, I covered the main implications (for AbbVie) of Humira's impending (2023) ...
"Interchangeability would change the game for Humira," Mohan said. It also would be a game-changer for biosimilars hoping to compete in the space, as it could give the interchangeable the advantage of ...
Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative. Alberta, Canada has expanded ...
LONDON, March 15 (Reuters) - Abbott Laboratories' drug Humira and Enbrel, from Pfizer and Amgen , should be the first choices for treating patients with psoriatic arthritis, Britain's ...
(Reuters) - Amgen Inc's cheaper version of AbbVie's top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug ...
Drugs to treat rheumatoid arthritis and other autoimmune diseases have been linked to tuberculosis cases in California, U.S. health officials said on Thursday. Twelve Californians who had taken the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback